New approaches for Helicobacter vaccine development - difficulties and progress

• Autorzy: Jagusztyn-Krynicka E K , Godlewska R.
• Języki publikacji: EN

Abstrakty

EN

Despite the enormous progress in understanding the process of bacterial pathogenesis and interactions of pathogens with eucaryotic cells the infectious diseases still remain the main cause of human premature deaths. It is now recognized that Helicobacter pylori infects about half of the world's population. Based on results of clinical studies the World Health Organization has assigned H. pylori as a class I carcinogen. The review presents new achievements aimed at construction efficient and safe anti-Helicobacter vaccine. We discuss the new global technologies such as immunoproteomics employed for selecting new candidates for vaccine construction as well as new vaccine delivery systems. The review presents also our knowledge concerning H. pylori interaction with immune system which might facilitate modulation of the host immune system by specific adjuvant included into vaccine.

Słowa kluczowe

EN

new vaccine; immunoproteomics; human disease; delivery system; vaccine; adjuvant; Helicobacter pylori

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2008
• Tom: 57
• Numer: 1
• Opis fizyczny: p.3-9,ref.

Twórcy

autor

Jagusztyn-Krynicka E K

• University of Warsaw, Miecznikowa 1, 02-096 Warsaw, Poland

autor

Godlewska R.

Bibliografia

• Aebischer T., A. Schmitt, A.K. Walduck and T.F. Meyer. 2005. Helicobacter pylori vaccine development: facing the challenge. Int. J. Med. Microbiol. 295: 343-353.
• Alm R.A., L.S. Ling, D.T. Moir, B.L. King, E.D. Brown, P.C. Doig, D.R. Smith, B. Noonan, B.C. Guild, B.L. de Jonge and athers. 1999. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397: 176-180.
• Angelakopoulos H. and E.L. Hohmann. 2000. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68: 2135-2141.
• Backert S„ T. Kwok, M. Schmid, M. Selbach, S. Moese, R.M. Peek, Jr., W. Konig, T.F. Meyer and P.R. Jungblut. 2005. Subproteomes of soluble and structure-bound Helicobacter pylori proteins analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5: 1331-1345.
• Baik S.C., K.M. Kim, S.M. Song, D.S. Kim, J.S. Jun, S.G. Lee, J.Y. Song, J.U. Park, H.L. Kang, W.K. Lee and others. 2004. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of Helicobacter pylori strain 26695. J. Bacteriol. 186: 949-955.
• Blaser M.J. and J.C. Atherton. 2004. Helicobacter pylori persistence: biology and disease. J. Clin. Invest. 113: 321-333.
• Bourzac K.M. and K. Guillcmin. 2005. Helicobacter pylori-host cell interactions mediated by type IV secretion. Cell Microbiol. 7: 911-919.
• Bumann D., S. Aksu, M. Wendland, K. Janek, U. Zimny-Arndt, N. Sabarth, T.F. Meyer and P.R. Jungblut. 2002. Proteome analysis of secreted proteins of the gastric pathogen Helicobacter pylori. Infect. Immun. 70: 3396-3403.
• Bumann D., P.R. Jungblut and T.F. Meyer. 2004. Helicobacter pylori vaccine development based on combined subproteome analysis. Proteomics 4: 2843-2848.
• Bumann D., W.G. Metzger, E. Mansouri, O. Palme, M. Wendland, R. Hurwitz, G. Haas, T. Aebischer, B.U. von Speeht and T.F. Meyer. 2001a. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 20: 845-852.
• Bumann D., T.F. Meyer and P.R. Jungblut. 2001b. Proteome analysis of the common human pathogen Helicobacter pylori. Proteomics 1: 473-479.
• Chmiela M. and P. Michetti. 2006. Inflammation, immunity, vaccines for Helicobacter infection. Helicobacter 11 Suppl 1: 21-26.
• Chuang M.H., M.S. Wu, J.T. Lin and S.H. Chiou. 2005. Proteomic analysis of proteins expressed by Helicobacter pylori under oxidative stress. Proteomics 5: 3895-3901.
• Corthesy B., S. Boris, P. Isler, C. Grangette and A. Mercenier. 2005. Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis. J. Infect. Dis. 192: 1441-1449.
• Cover T.L. and S.R. Blanke. 2005. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nature Rev. 3: 320-332.
• Dzwonek A., M. Mikula, M. Woszczynski, E. Hennig and J. Ostrowski. 2004. Protective effect of vaccination with DNA of the H. pylori genomie library in experimentally infected mice. Cell. Mol. Biol. Lett. 9: 483-495.
• Ferrero R.L. and A. Labigne. 2001. Helicobacter pylori vaccine development in the post-genomic era: can in silico translate to in vivo. Scand. J. Immunol. 53: 443-448.
• Fischer W., B. Gebert and R. Haas. 2004. Novel activities of the Helicobacter pylori vacuolating cytotoxin: from epithelial cells towards the immune system. Int. J. Med. Microbiol. 293: 539-547.
• Garmory H.S., K.A. Brown and R.W. Titball. 2002. Salmonella vaccines foruse in humans: present and future perspectives. FEMS Microbiol. Rev. 26: 339-353.
• Godlewska R., A. Dzwonek, M. Mikula, J. Ostrowski, M. Pawłowski, J.M. Bujnicki, and E.K. Jagusztyn-Krynicka. 2006. Helicobacter pylori protein oxidation influences the colonization process. Int. J. Med. Microbiol. 296: 321-4.
• Graham D.Y., A.R. Opekun, M.S. Osato, H.M. El-Zimaity, C.K. Lee, Y. Yamaoka, W.A. Qureshi, M. Cadoz and T.P. Monath. 2004. Challenge model for Helicobacter pylori infection in human volunteers. Gut 53: 1235-1243.
• Gressmann H., B. Linz, R. Ghai, K.P. Pleissner, R. Schlapbach, Y. Yamaoka, C. Kraft, S. Suerbaum, T.F. Meyer and M. Achtman. 2005. Gain and loss of multiple genes during the evolution of Helicobacter pylori. PLoS Gen. 1: e43.
• Haas G., G. Karaali, K. Ebermayer, W.G. Metzger, S. Lamer, U. Zimny-Arndt, S. Diescher, U.B. Goebel, K. Vogt, A.B. Roznowski and others. 2002. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2: 313-324.
• Hanniffy S., U. Wiedermann, A. Repa, A. Mercenier, C. Daniel, J. Fioramonti, H. Tlaskolova, H. Kozakova, H. Israelsen, S. Madsen and others. 2004. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv. Appl. Microbiol. 56: 1-64.
• Hatakeyama M. and T. Brzozowski. 2006. Pathogenesis of Helicobacter pylori infection. Helicobacter 11 Suppl 1: 14-20.
• Hatzifoti C, Y. Roussel, A.G. Harris, B.W. Wren, J.W Morrow and M. Bajaj-Elliott. 2006. Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter 11: 113-122.
• Kabir S. 2007. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12: 89-102.
• Kochi S.K., K.P. Killeen and U.S. Ryan. 2003. Advances in the development of bacterial vector technology. Exp. Rev. Vaccines 2: 31-43.
• Kotloff K.L., M.B. Sztein, S.S. Wasserman, CA. Losonsky, S.C. DiLorenzo and R.L Walker. 2001. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect. Immun. 69: 3581-3590.
• Krah A., F. Schmidt, D. Becher, M. Schmid, D. Albrecht, A. Rack, K. Buttner and P.R. Jungblut. 2003. Analysis of automatically generated peptide mass fingerprints of cellular proteins and antigens from Helicobacter pylori 26695 separated by two-dimensional electrophoresis. Mol. Cell Proteomics 2: 1271-1283.
• Lagergren J., R. Bergstrom, A. Lindgren and O. Nyren. 1999. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Eng. J. Med. 340: 825-831.
• Losonsky G.A., K.L. Kotloff and R.L Walker. 2003. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H. pylori seronegative individuals. Vaccine 21: 562-565.
• Łasica A.M. and E.K. Jagusztyn-Krynicka. 2007. The role of Dsb proteins of Gram-negative bacteria in the process of pathogenesis. FEMS Microbiol Rev. 31: 626-36.
• Marshall B. 2003. Helicobacter pylori: past, present and future. Keio J. Med. 52: 80-85.
• Marshall B.J. and J.R. Warren. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1: 1311-1315.
• Mini R., B. Annibale, E. Lahner, G. Bernardini, N. Figura and A. Santucci. 2006. Western blotting of total lysate of Helicobacter pylori in cases of atrophic body gastritis. Clin. Chem. 52: 220-226.
• Minoura T., S. Kato, S. Otsu, T. Fujioka, K. Iinuma and A. Nishizono. 2003. Childhood Helicobacter pylori infection in a murine model: maternal transmission and eradication by systemie immunization using bacterial antigen-aluminium hydroxide. Clin. Exp. Immunol. 134: 32-37.
• Moll H. 2004. Antigen delivery by dendritic cells. Int. J. Med. Microbiol. 294: 337-344.
• Naumann M. 2005. Pathogenicity island-dependent effects of Helicobacter pylori on intracellular signal transduction in epithelial cells. Int. J. Med. Microbiol. 295: 335-341.
• Malfertheiner P.. V. Schultze., G. Del Giudice, B. Rosenkranz, S.H.E Kaufmann, F. Winau, T. Ulrichs, E. Theophil, C.P. Jue, D. Novicki, and others. 2002. Phase 1 safety and immunogenicity of a three-component H. pylori vaccine. Gastroenterology 122 Suppl. 1, A585.
• Prinz C., N. Hafsi and P. Voland. 2003. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol. 11: 134-138.
• Raczko A.M., J.M. Bujnicki , M. Pawłowski, R. Godlewska, M. Lewandowska, and E.K. Jagusztyn-Krynicka. 2005. Characterization of new DsbB-like thiol-oxidoreductases of Campylobacter jejuni and Helicobacter pylori and classification of the DsbB family based on phylogenomic, structural and functional criteria. Microbiology 151: 219-31.
• Radosz-Komoniewska H., T. Bek, J. Jozwiak and G. Martirosian. 2005. Pathogenicity of Helicobacter pylori infection. Clin. Microbiol. Infect. 11: 602-610.
• Rizos K., C.T. Lattemann, D. Bumann, T.F. Meyer and T. Aebischer. 2003. Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains. Infect. Immun. 71: 6320-6328.
• Sabarth N., R. Hurwitz, T.F. Meyer and D. Bumann. 2002. Multiparameter selection of Helicobacter pylori antigens identifies two novel antigens with high protective efficacy. Infect. Immun. 70: 6499-6503.
• Salama N., K. Guillemin, T.K. McDaniel, G. Sherlock, L. Tompkins and S. Falkow. 2000. A whole-genome microarray reveals genetic diversity among Helicobacter pylori strains. Proc. Natl. Acad. Sci. USA 97: 14668-14673.
• Slonczewski J.L., D.J. McGee, J. Phillips, C. Kirkpatrick and H.L. Mobley. 2000. pH-dependent protein profiles of Helicobacter pylori analyzed by two-dimensional gels. Helicobacter 5: 240-247.
• Smythies L.E., M.J. Novak, K.B. Waites, J.R. Lindsey, C.D. Morrow and P.D. Smith. 2005. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease protect mice against H. pylori infection. Vaccine 23: 901-909.
• Sun B., Z.S. Li, Z.X. Tu, G.M. Xu and Y.Q. Du. 2006. Construction of an oral recombinant DNA vaccine from H. pylori neutrophil activating protein and its immunogenicity. World. J. Gastroenterol. 12: 7042-7046.
• Tomb J.F., O. White, A.R. Kerlavage, R.A. Clayton, G.G. Sutton, R.D. Fleischmann, K.A. Ketchum, H.P. Klenk, S. Gill, B.A. Dougherty and others. 1997. The complete genome seąuence of the gastric pathogen Helicobacter pylori. Nature 388: 539-547.
• Viala J., C. Chaput, I.G. Boneca, A. Cardona, S.E. Girardin, A.P. Moran, R. Athman, S. Memet, M.R. Huerre, A.J. Coyle and others. 2004. Nod 1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 5: 1166-1174.
• Xu C., Z.S. Li, Y.Q. Du, Z.X. Tu, Y.F. Gong, J. Jin, H.Y. Wu and G.M. Xu. 2005. Construction of a recombinant attenuated Salmonella typhimurium DNA vaccine carrying Helicobacter pylori hpaA. World J. Gastroenterol. 11: 114-117.
• Xu C, Z.S. Li, Y.Q. Du, Y.F. Gong, H. Yang, B. Sun and J. Jin. 2007. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H. pylori ureB and IL-2. World J. Gastroenterol. 13: 939-944.